company background image
UNRV

Unrivaled Brands OTCPK:UNRV Stock Report

Last Price

US$0.023

Market Cap

US$12.8m

7D

-20.2%

1Y

-91.3%

Updated

01 Oct, 2022

Data

Company Financials
UNRV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

UNRV Stock Overview

Unrivaled Brands, Inc. cultivates, produces, distributes, and retails medical and adult use cannabis products in California, Oregon, and Nevada.

Unrivaled Brands Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Unrivaled Brands
Historical stock prices
Current Share PriceUS$0.023
52 Week HighUS$0.45
52 Week LowUS$0.021
Beta2.37
1 Month Change-59.39%
3 Month Change-71.17%
1 Year Change-91.33%
3 Year Change-93.39%
5 Year Change-99.27%
Change since IPO-99.87%

Recent News & Updates

Shareholder Returns

UNRVUS PharmaceuticalsUS Market
7D-20.2%-0.04%-2.5%
1Y-91.3%3.2%-23.2%

Return vs Industry: UNRV underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: UNRV underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is UNRV's price volatile compared to industry and market?
UNRV volatility
UNRV Average Weekly Movement15.4%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: UNRV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: UNRV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010238Sabas Carrillohttps://www.unrivaledbrands.com

Unrivaled Brands, Inc. cultivates, produces, distributes, and retails medical and adult use cannabis products in California, Oregon, and Nevada. It also operates medical marijuana retail and adult use dispensaries, cultivation, and production facilities. The company was formerly known as Terra Tech Corp. and changed its name to Unrivaled Brands, Inc. in July 2021.

Unrivaled Brands Fundamentals Summary

How do Unrivaled Brands's earnings and revenue compare to its market cap?
UNRV fundamental statistics
Market CapUS$12.84m
Earnings (TTM)-US$104.84m
Revenue (TTM)US$81.03m

0.2x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UNRV income statement (TTM)
RevenueUS$81.03m
Cost of RevenueUS$57.27m
Gross ProfitUS$23.75m
Other ExpensesUS$128.59m
Earnings-US$104.84m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin29.32%
Net Profit Margin-129.39%
Debt/Equity Ratio44.2%

How did UNRV perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is UNRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UNRV?

Other financial metrics that can be useful for relative valuation.

UNRV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does UNRV's PS Ratio compare to its peers?

UNRV PS Ratio vs Peers
The above table shows the PS ratio for UNRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.5x
AYTU Aytu BioPharma
0.1x10.8%US$11.6m
VYNE VYNE Therapeutics
0.9x63.2%US$12.9m
CANB Can B
1.6x98.1%US$11.6m
CURR CURE Pharmaceutical Holding
3.4xn/aUS$18.4m
UNRV Unrivaled Brands
0.2xn/aUS$12.8m

Price-To-Sales vs Peers: UNRV is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does UNRV's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: UNRV is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Pharmaceuticals industry average (2.9x)


Price to Sales Ratio vs Fair Ratio

What is UNRV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UNRV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate UNRV's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of UNRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate UNRV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate UNRV's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Unrivaled Brands forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unrivaled Brands has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of UNRV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Unrivaled Brands's filings and announcements here.

Past Performance

How has Unrivaled Brands performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: UNRV is currently unprofitable.

Growing Profit Margin: UNRV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UNRV is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare UNRV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UNRV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: UNRV has a negative Return on Equity (-135.08%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Unrivaled Brands's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: UNRV's short term assets ($18.2M) do not cover its short term liabilities ($75.4M).

Long Term Liabilities: UNRV's short term assets ($18.2M) do not cover its long term liabilities ($27.6M).


Debt to Equity History and Analysis

Debt Level: UNRV's net debt to equity ratio (34.8%) is considered satisfactory.

Reducing Debt: UNRV's debt to equity ratio has increased from 1.9% to 44.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UNRV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: UNRV has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.1% each year.


Discover healthy companies

Dividend

What is Unrivaled Brands's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Unrivaled Brands Dividend Yield vs Market
How does Unrivaled Brands dividend yield compare to the market?
SegmentDividend Yield
Company (Unrivaled Brands)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Unrivaled Brands)n/a

Notable Dividend: Unable to evaluate UNRV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UNRV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UNRV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UNRV's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as UNRV has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.08yrs

Average management tenure


CEO

Sabas Carrillo (45 yo)

0.083yr

Tenure

Mr. Sabas Carrillo serves as Interim Chief Executive Officer of Unrivaled Brands, Inc. since August 12 2022 He serves as Chairman and Chief Executive Officer at Adnant Concepcion Acquisition Corp. He is an...


Leadership Team

Experienced Management: UNRV's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of UNRV?
Owner TypeNumber of SharesOwnership Percentage
Institutions7,347,3271.3%
Public Companies19,260,7423.5%
Private Companies24,881,7094.5%
Individual Insiders104,140,40818.8%
General Public399,178,70971.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.3%.


Top Shareholders

Top 18 shareholders own 28.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.96%
Dallas Imbimbo
44,186,284$1.0m0%no data
7.51%
Joseph Gerlach
41,662,529$964.5k0%no data
4.48%
Ravello Group, Llc
24,881,709$576.0k0%no data
3.47%
Singapore Telecommunications Limited
19,260,742$445.9k0%no data
1.32%
Equity IQ. LLC
7,308,059$169.2k0%no data
1.16%
Neda Imbimbo
6,454,752$149.4k0%no data
0.56%
Nicholas Kovacevich
3,105,459$71.9k0%no data
0.52%
Francis Knuettel
2,873,456$66.5k0%no data
0.4%
Michael Nahass
2,193,439$50.8k0%no data
0.26%
Eric Baum
1,451,698$33.6k0%no data
0.26%
Matthew Morgan
1,428,571$33.1k0%no data
0.063%
Uri Kenig
350,000$8.1k0%no data
0.051%
Jeffrey Batliner
284,220$6.6k0%no data
0.027%
Megan Jimenez
150,000$3.5k0%no data
0.0069%
KLCM Advisors, Inc.
38,000$879.70%no data
0.00011%
American Research & Management Co.
634$14.70%no data
0.00009%
CapFinancial Partners, LLC, Asset Management Arm
500$11.60%no data
0.00002%
Bartlett Wealth Management
134$3.10%no data

Company Information

Unrivaled Brands, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Unrivaled Brands, Inc.
  • Ticker: UNRV
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$12.844m
  • Shares outstanding: 554.81m
  • Website: https://www.unrivaledbrands.com

Number of Employees


Location

  • Unrivaled Brands, Inc.
  • 3242 S. Halladay Street
  • Suite 202
  • Santa Ana
  • California
  • 92705
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UNRVOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2012

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.